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Abstract  
Background: Although some studies have suggested that women with schizophrenia are more likely 
to achieve positive outcomes, the evidence-base is fraught with inconsistencies. In this study we 
compare the long-term course and outcomes for men and women living with schizophrenia in rural 
Ethiopia. 
Methods: The Butajira course and outcome study for severe mental disorder is a population-based 
cohort study. Community ascertainment of cases was undertaken between 1998 and 2001, with 
diagnostic confirmation by clinicians using the Schedules for Clinical Assessment in Neuropsychiatry. 
Findings from annual outcome assessments were combined with clinical records, patient and 
caregiver report, and psychiatric assessments at 10-13 years using the Longitudinal Interval Follow-
up Evaluation- LIFE chart. For the sub-group of people with schizophrenia (n=358), we compared 
course of illness and treatment, co-morbidity, recovery, social outcomes and mortality between men 
and women. Multivariable analyses were conducted modelling associations identified in bivariate 
analyses according to blocks shaped by our a priori conceptual framework of the biological and 
social pathways through which gender might influence the course and outcome of schizophrenia. 
Results: Looking into over 10-13 years of follow-up data, there was no difference in functioning or 
recovery in women compared to men (AOR= 1.79, 95% CI=0.91,3.57). Women were less likely to 
report overall life satisfaction (AOR=0.22, 95% CI=0.09 ,0.53) or good quality of spousal relationships 
(AOR=0.09, 95% CI=0.01-1.04). Men were more likely to have co-morbid substance use and there 
was a trend towards women being more likely to be prescribed an antidepressant (AOR=2.38, 95% 
CI=0.94, 5.88). There were no gender differences in course of illness, number of psychotic episodes 
or adherence to medications.  
Conclusion: In this rural African setting, we found little evidence to support the global evidence 
indicating better course and outcome of schizophrenia in women. Our findings are suggestive of a 
gendered experience of schizophrenia which varies across contexts. Further investigation is needed 
due to the important implications for the development of new mental health services in low and 
middle-income country settings. 
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Introduction 
Findings across a range of different outcomes are broadly consistent with a more positive course 
and outcome of illness for women living with schizophrenia compared to men diagnosed with the 
disorder [1, 2]. There is some heterogeneity in results and this is sometimes attributed to the effect 
of unmeasured ‘cultural’ factors [3]. For example, women are more likely to achieve functional 
remission than men [4], have less severe clinical symptoms, including a lower level of negative 
symptoms [3], although women have been found be more likely to have depression [5]. The 
pathways to these differences in outcomes could be partly shaped by underlying biology- for 
example, age of onset in women is generally 3-5 years later than that for men and early onset is 
associated with a range of worse outcomes, including social functioning; oestrogen may facilitate 
the effects of antipsychotics, causing women to have a better treatment response and therefore a 
better course of illness [6]. However, socioculturally constructed experiences of gender are also 
likely to play an important role in the differential outcomes between men and women living with 
schizophrenia. For example, in a study with 14 years of follow-up carried out in rural China, Ran et al 
found that men had higher rates of divorce, living alone, fewer caregivers, and families of men living 
with schizophrenia had lower economic status [3]. The authors suggest that women living with 
schizophrenia might be more readily accepted in rural China, receiving better social support, thus 
mediating more positive outcomes, including fewer negative symptoms. Similarly, authors of a 
longitudinal study carried out in urban India suggested that difficulties faced in achieving social 
norms of occupational functioning were a factor in shaping worse outcomes for men living with 
schizophrenia, compared to women, where economic dependence was more usual and less 
detrimental to continuing to receive social support [7].  
Study designs commonly used in high income country settings to understand the course and 
outcome of schizophrenia have limited utility in low and middle-income country. For example, 
longitudinal studies are either: incidence cohorts recruited at the time of first episode of psychotic 
illness [8-10], or studies which examined outcomes for inpatients discharged from specialist care 
settings [11, 12].. In LMIC, where the vast majority of men and women living with schizophrenia do 
not access biomedical health services, or do so many years after onset of illness [13], prospective 
studies which start early in the course of disease are not feasible: comparable studies would require 
large-scale community recruitment, which is uncommon [14, 15]. This has resulted in an evidence-
base which consists largely of research from HIC, with limited knowledge on the course of illness in 
LMIC. There is an overall lack of understanding of the potential for sociocultural differences to 
influence outcomes, although this was noted as a possibility by researchers carrying out cross-
national studies in the 1990s [16]. Research on the effects of gender in LMIC is complicated further 
by other methodological challenges which mean that it has been difficult to ascertain the true extent 
of differences between men and women in the course and outcome of schizophrenia. Research on 
this topic tends to be secondary data analysis, meaning that often, sample sizes of men and women 
are insufficient for detailed analyses [1] and there is a lack of data available on potential 
confounders of associations between gender and course and outcome, for example: social support, 
autonomy, help-seeking. Despite these difficulties, there are a few notable examples of longitudinal 
studies carried out in LMIC settings which have provided important contributions to the evidence-
base about the potential for differences in course and outcome of schizophrenia between men and 
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women. This includes Ran et al (rural China, 14 years of follow-up, n=265 women, n=224 men) who 
found that men had lower survival, and higher rates of suicide and were more likely to be: single or 
divorced, or homeless compared to women [3]; as well as Gureje and Bamidele (urban Nigeria, 13 
years of follow-up, n=64 women, n=56 men) who found that although women had a more benign 
course of illness and were more likely to be married, they were more likely to report lower 
frequency and quality of social contact [17, 18]. These studies notwithstanding, the vast majority of 
evidence about gender and schizophrenia comes from studies carried out in HIC. Given that 
sociocultural constructions of gender, norms of social roles of men and women and support differ 
across settings, the extent to which findings are generalizable outside of the context in which the 
studies were undertaken is uncertain. 
The research presented here is the result of a comprehensive analysis of longitudinal outcomes of 
schizophrenia in relation to gender, using long-term follow-up data from the Butajira cohort, the 
only community-based long-term study of people living with Severe Mental Illness (SMI) in a low 
income, rural sub-Saharan African setting. This work builds upon previous analysis of data from the 
Butajira cohort which examined baseline cross-sectional associations with course of illness [15] and 
both short-term (mean= 3.4 years) [19] and longer-term outcomes (Psychiatric Status Rating, 
pattern of illness, mortality) [20]. Gender was not the primary focus of these studies, but several 
findings indicated gender differences that warranted further investigation. Although it is generally 
accepted that, the prevalence of schizophrenia is equal among men and women [21], among the 
Butajira cohort it was much higher, with men outnumbering women by a ratio of almost five to one. 
Authors concluded that this difference was not explained by either differential out-migration or 
mortality among the general population, as there were no sex differences among non-participants in 
the study [15, 22]. Five-year mortality for all participants living with schizophrenia was found to be 
six times higher than that found in the general population and higher for men than for women (6.3 
versus 4.3, respectively) [23]. Over a 10-year period, although mortality was higher among men 
compared to women (19.3% compared to 12.9%), this difference was not statistically significant [24]. 
All of those who died due to suicide were male (n=9), but again, this difference was not statistically 
significant [20, 24]. Mental health status scores of women appeared to be slightly better than those 
of men with every year of follow-up [20]. In contrast with results from a recent meta-analysis [25], 
among the Butajira cohort, men were found to have a later age of onset of psychotic symptoms 
compared to women. Authors suggested that this might be due to selection bias- with only women 
exhibiting the most severe disorder recognized as having the disorder [15]. Other findings perhaps 
reflected the disadvantage of women in Ethiopian society, compounded by the presence of SMI: 
men living with schizophrenia were more likely to be married, better educated and employed than 
women living with the disorder [22].  
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The aim of our analyses was to investigate impact of gender/sex upon the course and outcome of 
schizophrenia, from the perspective of long-term follow-up of participants from a rural, low income 
country in a sociocultural context different from that of most published studies. As described in 
Figure 1, following our review of the literature, we constructed a conceptual framework which we 
used as the basis for analyses, separating differences in outcomes between men and women which 
are more likely to be driven by biological factors (e.g. those associated with sex) and those shaped 
by sociocultural construction (e.g. those associated with experiences of gender).  
Methods 
Results presented here are based on analysis of data from 10-13 years follow-up of 358 people with 
a diagnosis of schizophrenia from the Butajira cohort study on people living with SMI in rural 
Ethiopia. Study methods, including selection of measures and results from the study have been 
described in detail elsewhere e.g. [15, 22, 24, 26]. 
Setting 
Butajira is a rural district of Ethiopia located 135 kilometres south-west of Addis Ababa. In 1998, at 
the time of initiation of the cohort, the surrounding district of Meskan and Mareko had a population 
of 227,135 people. The district was divided into 45 sub-districts, four of which are located in Butajira 
town (urban). Butajira has hosted a Demographic Surveillance Site since 1987. At the start of the 
cohort, there was one health centre and five health stations located in the district. A hospital was 
opened in Butajira in 2001. Until the initiation of the Butajira Cohort Study, in which mental health 
care, including medication was provided free of charge, there was no mental health care available 
within the district. The vast majority of people living with SMI were naïve to biomedical treatment 
prior to participation in the study but had commonly accessed traditional medicine for their illness 
[27]  . 
The Butajira Cohort Study 
The cohort was initiated in 1998, with a door-to-door survey of adults of reproductive age (15-49 
years). A two-stage screening process was used to identify people living with schizophrenia, bipolar 
disorder and severe major depression. Out of an estimated population of 83,282, a total of 68,378 
people were screened using the Composite International Diagnostic Interview (CIDI 2.1), out of 
which 53.0% were female [22]. In addition, key informants from each village within the community 
were asked to identify people they thought might be living with SMI. This yielded 719 in total with a 
possible diagnosis of schizophrenia. The Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN) was used as the second stage of screening, resulting in 321 (54 Women and 267 men) with a 
diagnosis of schizophrenia [15]. Out of all subjects invited for the SCAN interview, 38.0% were 
female [28] . Forty additional incident cases were identified using a similar diagnostic process during 
the first two years of the cohort. The main advantage of the LIFE chart is that data from participants 
can be included up until a censor point; for example, death, refusal, loss to follow-up. For the 
analyses presented here, the sample size was 358 (3 participants were excluded due to missing 
data). The first stage of screening (CIDI) was carried out by trained interviewers (local high school 
graduates, employed via competitive recruitment); the SCAN was administered by medical doctors 
with experience in mental health care. Variables on age at first prodromal symptoms and age at first 
recognition of disorder were derived from the SCAN. 
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Follow-up data on participants was collected at monthly clinical appointments held at the research 
centre in Butajira town. The same project workers originally employed to carry out screening invited 
and supported participants to attend monthly appointments, including organising home visits where 
necessary. Psychiatric nurses carried out a clinical assessment at each appointment, which included: 
assessment of clinical state during the preceding month, presence/absence of psychotic symptoms, 
use of medication, whether the patient was in episode/remission at the time of the appointment; 
suicidality; alcohol and Khat use. Patient deaths were recorded (described as mortality in Table 2). In 
addition to the monthly clinical assessment, the following research instruments were administered 
annually: Schedules for Clinical Assessment in Neuropsychiatry (SCAN) [29], Scales for Assessment of 
Positive Symptoms (SAPS), Scales for Assessment of Negative Symptoms (SANS) [30], Global 
Assessment of Functioning [31]. Medication (first generation psychotropics and antidepressants) 
was available free of charge and was prescribed according to clinical indication.  
Long-term outcomes were collected in 2012 using the Longitudinal Interval Follow-up Evaluation 
(LIFE) chart data [32]. Validated in diverse settings, and previously used in Ethiopia, the LIFE chart is 
a semi-structured questionnaire, designed to be used by clinicians to effectively summarise 
longitudinal clinical data. Primary rating scales for the LIFE chart include the Psychiatric Status Rating 
(PSR), used in the Butajira cohort (and elsewhere [33, 34]) as an instrument to help clinicians capture 
the severity of symptoms at each monthly (or weekly) visit since enrollment: in our case enabling 
annual summarization of psychopathology and functional status of participants over 10-13 years of 
follow-up. For the Butajira study, four psychiatrists were trained in the LIFE chart approach [35].The 
PSR ratings were carried out using all available information: reports by patients and their caregivers 
following face to face interviews, family and psychiatric nurses, monthly clinical records, annual 
symptomatic and functional ratings, and reports from the project outreach workers who had 
monthly contacts with people living with severe mental disorders and their families [35].  SAPS and 
SANS scores are included as an input for the PSR and so only baseline SAPS and SANS scores are 
reported separately in our results (Table 1). Hamilton Depression Scale [36] was administered by 
psychiatrists or psychiatric trainees. Psychiatric Status Rating scores (where a score of 1-2 indicating 
remission, 3-4 suggestive of partial remission and 5-6 indicating that the participant was 
experiencing a psychotic episode) were used as the basis of course of illness variables: number of 
psychotic episodes; percentage of individual patient’s follow-up time spent in remission. We 
developed two recovery variables: more than 6 consecutive months spent in remission and more 
than 12 consecutive months spent in remission. Also derived from the LIFE Chart were variables 
related to psychosocial functioning: interpersonal relationships (with separate ratings for spouse, 
children, other important relatives); social adjustment; sexual enjoyment; life satisfaction; all of 
which were structured as six to eight-point ordinal rating scales, with detailed descriptions of each 
category. For example: poor for interpersonal relationships is described as “regularly argues with 
family members (often not resolved), prefers avoiding contact/feels deficit in emotional closeness, 
derives no pleasure from contact”; whereas very good is defined as: “ experiences good 
relationships with family members, with only transient friction, rapidly resolved, feels only 
minor/occasional need to improve relationship, which is close and satisfying”[32]. Carer burden and 
experience of stigma scores were derived from the Family Interview Schedule [37]. We also 
examined treatment, using the following variables: percentage of individual patient’s follow-up time 
spent in treatment, percentage of individual patient’s follow-up time spent on antipsychotics, 
percentage of individual patient’s follow-up time spent on antidepressants, percentage medication 
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adherence over follow-up period: calculated using number of prescriptions recorded as the 
denominator and self-reported number of prescriptions collected from pharmacies as the 
numerator.  
Analysis 
The overall approach was to stratify and compare outcomes by gender. We described study 
participants at baseline stratified by sociodemographic characteristics and current clinical state 
(entry into clinical care) using proportions, chi squared and t tests. We also calculated odds ratios, 
where appropriate. Using variables derived from the LIFE chart data, we carried out bivariate 
analysis using chi-square and calculated  odds ratio to examine associations between gender and the 
following outcomes: course of illness and treatment (recovery, time spent in remission, number of 
psychotic episodes, time on treatment- antipsychotic, antidepressant, adherence), co-morbidity, 
mortality and social outcomes (functioning, adjustment, satisfaction, employment, stigma, quality of 
relationships). Finally, we carried out multivariable analyses, modelling associations identified in 
bivariate analyses according to blocks shaped by our a priori conceptual framework of the pathways 
through which gender might influence the course and outcome of schizophrenia, models included: 
1. proxy indicators of biological factors (baseline clinical state, age at first prodromal symptoms); 2. 
recovery and 3. recovery adjusted for adherence to follow-up appointments; 4. medication; 5. social 
outcomes. All models were adjusted for possible confounders: urban/rural residence, age at 
recognition of illness. Urban/rural residence was found to be associated with sex [22] and was 
hypothesised to have an effect upon identification of mental illness, help-seeking behaviour and 
access to healthcare. Similarly, age at first recognition of illness was previously found to be 
associated with sex [15] and expected to be associated with course of illness outcomes. Models 2,3 
and 5 were adjusted for present clinical state rating at baseline and age at first prodromal 
symptoms. Model 4 was adjusted for baseline depressive symptoms.  
Results 
Three hundred and fifty-eight participants in the Butajira cohort with a diagnosis of schizophrenia 
and complete follow-up data were included in our analyses (62 women and 296 men, see Table 1). 
Women were more likely to be divorced/separated or widowed; less likely to be literate; had a 
younger age of onset and an earlier age of first recognition of illness. At baseline, women were more 
likely to be in remission and there was no gender difference in positive or negative mean symptom 
scores or social functioning. 
Table 2. describes crude associations between gender and a range of clinical and social outcomes. 
There was only weak evidence that women had more positive outcomes than men in terms of being 
more likely to have more than 12 consecutive months in remission; being more likely to spend more 
than 75 percent of the time in remission. Despite no difference in symptoms of depression between 
men and women, women were more likely to spend a higher proportion of time on antidepressants. 
There was no difference in overall proportion of time spent on any treatment, but women had 
better adherence and were more likely than men to spend a high proportion of time (more than 75 
percent) on antipsychotic medication. In terms of social outcomes: women were more likely to 
report lower overall life satisfaction as well as less satisfaction with spousal relationships. Men were 
more likely to use khat/alcohol. 
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Table 3. describes the results of multivariable analyses. Model 1. Shows that there was strong 
evidence that men were more likely to be in episode at baseline (AOR=3.41, 95% CI=1.08-10.74) and 
a trend towards older age at first prodromal symptoms (AOR=2.62, 95% CI=0.93-7.36). Models 2 and 
3 show that after adjusting for adherence (attendance of follow-up appointments) the trend 
towards association of recovery with female sex disappears (AOR=0.62, 95% CI=0.30-1.27). Model 4. 
Demonstrates that after adjusting for baseline depressive symptoms, a trend towards women being 
more likely to spend a high proportion of time on antidepressants remained (AOR=0.42, 95% 
CI=0.17-1.06). Finally, Model 5. Shows that women generally had worse social outcomes, being less 
satisfied overall, less likely to be satisfied with spousal relations and more likely to be 
divorced/widowed. 
Discussion 
In our analysis of data from the Butajira cohort in rural Ethiopia, we found little evidence to suggest 
that women experienced more positive outcomes. There was no difference in functioning and 
recovery, once models were adjusted for confounders. In terms of social outcomes, specifically, 
overall life satisfaction and quality of spousal relationships, women had worse outcomes. This is in 
the context of much higher khat/alcohol use among men and more time spent on antidepressants 
by women, despite similar levels of depressive symptoms between men and women (at baseline).  
The patterns of both prevalence and age of onset among men and women found among the Butajira 
cohort are in contrast to those found in the majority of studies from both high and low and middle-
income settings. For example, the most recent analysis of Global Burden of Disease data found no 
sex difference in prevalence and no evidence to support the development of schizophrenia at a later 
age among women [21]. A key potential limitation to the robustness (and generalisability) of our 
findings is the extent to which men and women living with schizophrenia included in the study may 
be considered representative of people living with the disorder in the Butajira community. The 
community-based design is a key strength in a setting where the vast majority of people living with 
SMI were naïve to biomedical treatment before the initiation of the study. The design is unusual, 
particularly when compared to other longitudinal studies carried out in sub-Saharan Africa, which 
have tended to be clinic-based [17, 38].  Although we adjusted final models for age of onset to 
adjust for selection bias, it is unlikely that this was fully effective in controlling for differential entry 
into the cohort by men and women. A possible explanation is, that in this setting, only women 
exhibiting the most severe symptoms are commonly recognized as having schizophrenia. 
Alternatively, patterns of arranged marriage in which women have little autonomy, marry young and 
move away from their families may provide a trigger for early onset or earlier recognition of 
symptoms [22]. Further research is required to understand the true nature of the observed 
association between being female and early onset in this setting. The small number of female 
participants poses a practical challenge to robust analysis. Insufficient power to detect a difference 
in outcomes cannot be ruled out as an explanation for our findings. There was no standardized 
measure of adherence: this was based on self-reported collection of prescriptions- this measure is 
therefore subject to recall and social desirability bias. Women were treated with antidepressant 
medications more than men during the follow-up period. There was no significant between group 
difference in the negative symptoms score at baseline, and ratings were completed by trained 
psychiatrists who could reasonably be expected to be able to differentiate between negative and 
depressive symptoms. Therefore, the higher proportion of time that women spent on 
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antidepressant medications can fairly be attributed to depressive symptoms rather than negative 
symptoms of schizophrenia. 
Our research contributes to a small evidence-base which examines differences in social outcomes 
between men and women living with schizophrenia in LMIC. It should be noted that the global 
evidence-base is equivocal, with a recent meta-analysis showing no difference in recovery (defined 
as improvements in both clinical and social domains and evidence that improvements in at least 1 of 
these 2 domains had persisted for at least 2 years)[39]. Only 5 of the 50 studies included in this 
meta-analysis came from a low income country setting: it seems likely that differences may be more 
prominent in some LMIC settings where social norms linked to life expectations and indications of 
success are arguably more strongly gendered. In an early study carried out in Nigeria which used 
review of clinical records to assess outcomes over time, men had better social adjustment [38].  In 
their 13-year follow-up study of outpatients in an urban centre in South-West Nigeria, Gureje and 
Bamidele noted that in their sample, women exhibited a greater degree of impairment in terms of 
frequency and quality of social contact.  Although women were more likely to have ever married, 
data about the quality and nature of marriage and spousal relationships was not collected in this 
study [17] . However, it seems possible that women’s illness may be either less apparent at the 
younger age at which they are expected to get married or, alternatively, that their symptoms are 
more easily concealed, which may be desirable given the stigma with which they are associated [40]. 
In India, it was suggested that, whereas women were likely to be blamed for not conceiving or 
performing caregiving and homemaking duties effectively (responsibilities only taken on after 
marriage); men were blamed for their inability to hold down a stable job (a likely criterion for getting 
married) [41].  In contrast, in two year follow-up study conducted in rural China, the authors 
suggested that more positive clinical outcomes among women could be attributed to women living 
with schizophrenia being more able to perform their expected role- housework, childcare and some 
farm-work and that this social functioning helped to prevent clinical deterioration [42]. Given that 
we understand that gender roles, expectations and experiences are culturally mediated and that 
together they exercise a strong influence upon health and illness, it is to be expected that 
experience of living with schizophrenia will be mediated by sociocultural constructions of gender. 
We should therefore anticipate gendered differences in outcome, with variation in different 
sociocultural contexts. These differences have important implications for both future research and 
development of new services and are currently neglected.  
Recognition of the importance of gender in SMI research in LMIC will be needed to ensure that 
studies are designed in such a way as to: generate robust estimates for differences in outcomes; 
understand the determinants of these. Like other similar studies, ours was potentially under-
powered to detect and investigate differences by gender. Efforts should be made to ensure 
sufficient sample sizes to support multivariable analyses to robustly analyse gender differences. 
Case-finding strategies to identify women living with schizophrenia who may be “hidden” may be 
necessary: for example, snowball sampling among health service providers, religious and traditional 
healers, other key informants in communities may be needed to achieve a representative sample 
[43]. Prior to this, qualitative research would contribute to improved understanding of potential 
reasons for differential inclusion in a community-based study: to explore whether idioms of distress, 
explanatory models of illness (of the person living with schizophrenia, their families and the 
community) and the nature of the clinical/research encounter vary according to gender. Results of 
this kind of work would help us to understand whether the unusual pattern of age of onset and 
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prevalence represent a ‘true’ but unexplained difference or are a result of social construction which 
potentially risks inhibiting equality of access to services among men and women. This will be a 
necessary component of research around the design, implementation and scale-up of new mental 
health services in LMIC. These services will inevitably be task-shared, with much of the mental health 
care delivered by non-specialists [44-46]. Training which is adapted to the local context will be 
essential if these services are to be equitable [47, 48] .  
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Table 1. Associations with baseline sociodemographic and clinical characteristics 
 









  62 (17.3) 296 (82.7)    
Sociodemographic       
Age in years < 20 11 (17.7) 16 (5.5)   Ref 
 20-29 20 (32.3) 116 (40)   0.26 (0.10-0.64)  
 30-39 20 (32.3) 109 (37.6)   0.27 (0.15-0.68) 
 40+ 11 (17.7) 49 (16.9) 11.16 (df=3) 0.01 0.34 (0.11-0.93) 
Marital status Single 32 (51.6) 170 (57.4)   Ref 
 Married  14 (22.6) 91 (30.7)   0.82 (0.41-1.61) 
 Divorced/separated 11 (17.7) 30 (10.1)   1.95 (0.88-4.31) 
 Widowed 5 (8.1) 5 (1.7) 11.52 (df=3) 0.01 5.31 (1.41-20.0) 
Residence Urban 21 (33.9) 66 (22.3)   Ref 
 Rural 41 (66.1) 230 (77.7) 3.73 (df=1) 0.05 0.56 (0.31-1.02) 
Education Non-literate 44 (71.0) 145 (50.3)   Ref 
 Literate 18 (29.0) 143 (49.7) 8.73 (df=1) <0.01 0.41 (0.23-0.76) 
Onset of disorder       
Age at first prodromal 
symptoms 
15 years or less  29 (48.3) 85 (32.8)   Ref 
 16-24 20 (33.3) 85 (32.8)   0.24 (0.14-0.38) 
 >25 11 (18.3) 89 (34.4) 7.28 (df=2) 0.03 0.12 (0.07-0.23) 
Age at first recognition of 
disorder  
15 years or less  11 (18.6) 18 (6.6)   Ref 
 16-24 29 (49.2) 127 (46.5)   0.37(0.16-0.89) 
 >25 19 (32.2) 128 (46.9) 10.50 (df=2) 0.01 0.24 (0.10-0.61) 
Clinical state at entry into care       
Entry duration of illness  <2 years 14 (23.3) 63 (24.2) 0.02 (df=1) 0.88 0.95 (0.49-1.85) 
Psychiatric Status Rating (PSR) Remission 8 (13.0) 10 (3.4)   Ref 
 Partial remission 5 (8.1) 52 (17.5)   0.12 (0.03-0.51) 
 In episode 49 (79.0) 234 (79.1) 17.16 (df=2) <0.01 0.26 (0.10-0.71) 
Positive symptoms score 
(n=316) 
Mean score 6.2 (4.8-
7.6) 
6.4 (5.9-7.0) t=-0.36 (df=314) 0.72 -0.002 (-0.01-
0.01) 
Negative symptoms score 
(n=316) 






t=0.40 (df=314) 0.69 0.001 (-0.001-
0.23) 
Social functioning (GAF) Mild/minimal 
impairment 
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Table 2. Associations with clinical and social outcomes 
 
Characteristic  Female Male Chi-squared P-Value OR (95% CI) 
(men= comparison group)_ 
  Course of illness       
Recovery (>12 consecutive months 
in remission) 
 17 (27.9) 58 (20.0) 2.09 (df=1) 0.15 1.58 (0.84-2.98) 
Recovery (>6m consecutive 
months in remission) 
 40 (65.6) 172 (58.1) 1.17 (df=1) 0.28 1.37 (0.77-2.45) 
Percent time spent in remission <25 28 (45.2) 172 (58.1)   Ref 
 25-49 10 (16.1) 36 (12.2)   0.37 (0.16-0.89) 
 50-74 6 (9.7) 37 (12.5)   0.24 (0.10-0.61) 
 >75 18 (29.0) 51 (17.2) 6.21 (df=3) 0.10 2.17 (1.10-4.27) 
  Treatment       
% time in treatment <25 21 (33.9) 129 (43.6)   Ref 
 25-49 14 (22.60) 65 (22.0)   1.32 (0.63-2.78) 
 50-74 10 (16.1) 45 (15.2)   1.37 (0.60-3.13) 
 >75 17 (27.4) 57 (19.3) 2.84 (df=3) 0.42 1.83 (0.89-3.75) 
% time on antipsychotic <25 34 (54.8) 174 (58.8)   Ref. 
 25-49 13 (21.0) 53 (17.9)   1.30 (0.65-2.59) 
 50-74 5 (8.1) 53 (17.9)   0.45 (015-1.35) 
 >75 10 (16.1) 23 (7.8) 6.29 (df=3) 0.10 2.21 (0.96-5.11) 
% time on antidepressant <25 50 (80.7) 270 (91.2)   Ref. 
 25-49 2 (3.2) 13 (4.4)   0.83 (0.18-3.80) 
 50-74 3 (4.8) 6 (2.0)   2.70 (0.65-11.23) 
 >75 7 (11.3) 7 (2.4) 12.86 (df=3) 0.01 5.40 (1.78-16.40) 
Medication adherence <25%  12 (19.4) 63 (21.3)   Ref 
 25-49% 9 (14.5) 47 (15.9)   1.01 (0.39-2.59) 
 50-75% 12 (19.4) 62 (20.9)   1.02 (0.42-2.44) 
 >75% 28 (45.2) 116 (39.2)   1.27 (0.60-2.67) 
 Not 
prescribed 
1 (1.6) 8 (2.7) 0.91 (df=4) 0.92 0.66 (0.07-5.83) 
Adherence to follow up 
appointments 
<25%  14 (22.6) 82 (27.7)   Ref 
 25-49% 4 (6.5) 48 (16.2)   0.49 (0.15-1.58) 
 50-75% 15 (24.2) 63 (21.3)   1.39 (0.62-3.11) 
 >75% 29 (46.8) 103 (34.8) 6.1 (df=3) 0.11 1.65 (0.81-3.34) 
  Social outcomes       
Social functioning (GAF) Mild/ 
minimal 
impairment 
21 (33.9) 88 (29.7) 0.66 (df=2) 0.72 1.21 (0.68-2.17) 
Social adjustment Fair-very 
good 
27 (43.5) 108 (36.5) 1.09 (df=1) 0.30 1.34 (0.77-2.34) 
Satisfaction Fair-very 
good 
45 (72.6) 250 (84.5) 4.99 (df=1) 0.03 0.49 (0.26-0.93) 
Mean stigma score 0 6 (9.8) 38 (13.6)   Ref 
 0-1 36 (59.0) 176 (63.1)   1.30 (0.51-3.30) 
 >1 19 (31.2) 65 (23.3) 1.94 (df=2) 0.38 1.85 (0.67-5.09) 
Mean carer burden score 0 11 (18.0) 52 (18.6)   Ref 
 0-1 12 (19.7) 75 (26.7)   0.76 (0.31-1.85) 
 1-2 17 (27.9) 74 (26.5)   1.09 (0.47-2.52) 
 2-3 21 (34.4) 78 (28.0) 1.78 (df=3) 0.62 1.27 (0.56-2.87) 
  Quality of relationships       
Parents No 
relationships  
24 (38.7) 102 (34.5)   Ref 
 Fair-very 
good 
32 (51.6) 153 (51.7) 0.94 (df=2) 0.62 0.89 (0.49-1.60) 
Siblings No 
relationships  
4 (6.5) 10 (3.4)   Ref 
 Fair-very 
good 
48 (77.4) 231 (78.0) 1.41 (df=2) 0.49 1.14 (0.54-2.40) 
Spouse No 51 (82.3) 190 (64.2)   Ref 
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relationships  
 Fair- very 
good 
11 (17.7) 98 (33.1) 8.1 (df=2) 0.02 0.42 (0.21-0.84) 
Children No 
relationships  
33 (53.2) 168 (56.8)   Ref 
 Fair- very 
good 
27 (43.5) 114 (38.5) 0.70 (df=2) 0.70 1.21 (0.69-2.12) 
Friends Poor 165 (83.3) 131 (81.9)   Ref 
 Fair- very 
good 
33 (53.2) 165 (55.7) 0.13 (df=1) 0.72 1.11 (0.64-1.92) 
 No 
relationships 
0 (0) 0 (0)    
  Co-morbidity and mortality       
Hamilton Depression scale <8 44 (71) 218 (73.6)   Ref 
 9-15 8 (12.9) 39 13.2)   1.23 (0.59-2.58) 
 16-22 0 (0) 3 (1.0)   0.86 (0.10-7.36) 
 >23 10 (16.1) 36 (12.2) 1.3 (df=3) 0.73 1.36 (0.62-2.95) 
Alcohol/khat abuse  3 (4.8) 114 (38.5) 26.4 (df=1) <0.01  
Suicide attempt(s)   12 (19.4) 35 (11.8) 2.5 0.11 1.79 (0.87-3.70) 
Mortality Deceased 8 (12.9) 57 (19.3) 1.4  0.24 0.62 (0.28-1.38) 
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 Table 3. Multivariate analyses 
 
Model Explanatory variable Category AOR (95% CI) P-value 
Model 1. Biological factors Baseline present state 
rating 
Remission 1.00  
  Partial remission 0.11 (0.03-0.48) <0.01 
  In episode 0.29 (0.09-0.93) 0.04 
 Age at first prodromal 
symptoms 
<15 1.00  
  16-24 0.78 (0.34-1.79) 0.56 
  >25 0.38 (0.14-1.08) 0.07 
     
Model 2. Recovery Recovery Less than 12m continuous 
remission 
1.00  
  At least 12m continuous 
remission 
1.79 (0.91-3.57) 0.09 
     
Model 3. Recovery + 
adherence to follow-up 
appointments 
Recovery Less than 12m continuous 
remission 
1.00  
  At least 12m continuous 
remission 
1.61 (0.79-3.33) 0.19 
 Adherence to follow-up 
appointments 
<25% 1.00  
  25-49% 0.37 (0.10-1.43) 0.15 
  50-75% 1.35 (0.56-3.23) 0.50 
  >75% 1.27 (0.56-2.86) 0.57 
     
Model 4. Medication  Time on antipsychotics <75% 1.00  
  >75% 2.33 (0.78-6.67) 0.13 
 Time on antidepressants <75% 1.00  
  >75% 2.38 (0.94-5.88) 0.07 
Model 5. Social outcomes Overall satisfaction Poor- very poor 1.00  
  Fair-very good 0.22 (0.09-0.53) <0.01 
 Marital status at endline Single 1.00  
  Married 3.85 (0.35-1.00) 0.27 
  Separated/divorced 3.03 (1.28-7.14) 0.01 
  Widowed 1.49 (3.13-100.00) <0.01 
 Quality of spousal 
relationship 
No relationship 1.00  
  Fair-very good 0.09 (0.01-1.04) 0.05 
 Satisfaction with sexual 
relations 
Dissatisfied 1.00  
  No information given 2.86 (0.76-10.0) 0.12 
  Satisfied 4.35 (1.25-14.29) 0.02 
 Employment  Yes 1.00  
  No- psychopathology 0.74 (0.35-1.54) 0.42 
  No- other reason 6.25 (0.91-50.00) 0.06 
All models adjusted for urban/rural residence; age at recognition of illness 
Models 2, 3 & 5 also adjusted for baseline present state rating; age at first prodromal symptoms 
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Figure 1. Conceptual framework: possible associations of female sex and female gender with course and outcomes of schizophrenia in LMIC settings 
KEY: strength of evidence from 
literature 
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